127 related articles for article (PubMed ID: 33459635)
1. Weight gain during pregnancy in women with HIV receiving different antiretroviral regimens.
Floridia M; Masuelli G; Tassis B; Franceschetti L; Savasi VM; Spinillo A; Tamburrini E; Guaraldi G; Dalzero S; Sansone M; Chiodo A; Antoni AMD; Pinnetti C; Liuzzi G; Ravizza M;
Antivir Ther; 2020; 25(6):315-325. PubMed ID: 33459635
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study.
Floridia M; Dalzero S; Giacomet V; Tamburrini E; Masuelli G; Savasi V; Spinillo A; Tassis B; Franceschetti L; Degli Antoni AM; Sansone M; Guaraldi G; Vimercati A; Meloni A; Ravizza M;
Infection; 2020 Apr; 48(2):249-258. PubMed ID: 31893354
[TBL] [Abstract][Full Text] [Related]
3. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.
Floridia M; Mastroiacovo P; Tamburrini E; Tibaldi C; Todros T; Crepaldi A; Sansone M; Fiscon M; Liuzzi G; Guerra B; Vimercati A; Vichi F; Vicini I; Pinnetti C; Marconi AM; Ravizza M;
BJOG; 2013 Nov; 120(12):1466-75. PubMed ID: 23721372
[TBL] [Abstract][Full Text] [Related]
4. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
5. In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database.
Saint-Lary L; Diallo A; de Monteynard LA; Paul C; Marchand L; Tubiana R; Warszawski J; Mandelbrot L; Rekacewicz C; Petrov-Sanchez V; Faye A; Sibiude J; Dabis F; Sommet A; Leroy V
Br J Clin Pharmacol; 2022 Mar; 88(3):942-964. PubMed ID: 34505718
[TBL] [Abstract][Full Text] [Related]
6. Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study.
Martínez-Sanz J; Blanco JR; Muriel A; Pérez-Elías MJ; Rubio-Martín R; Berenguer J; Peraire J; Bernal E; Martínez OJ; Serrano-Villar S; Moreno S;
J Int AIDS Soc; 2021 May; 24(5):e25732. PubMed ID: 34036745
[TBL] [Abstract][Full Text] [Related]
7. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
[TBL] [Abstract][Full Text] [Related]
8. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
9. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
Szyld EG; Warley EM; Freimanis L; Gonin R; Cahn PE; Calvet GA; Duarte G; Melo VH; Read JS;
AIDS; 2006 Nov; 20(18):2345-53. PubMed ID: 17117021
[TBL] [Abstract][Full Text] [Related]
10. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
11. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
Senise JF; Castelo A; Martínez M
AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
[TBL] [Abstract][Full Text] [Related]
12. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
13. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
15. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
16. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
18. [Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].
Cervero M; Torres R; Jusdado JJ; Pastor S; Agud JL
Med Clin (Barc); 2016 Apr; 146(8):339-45. PubMed ID: 26971988
[TBL] [Abstract][Full Text] [Related]
19. Effect of tenofovir alafenamide in combination with and without integrase inhibitors on weight gain, diabetes, and hypertensive disorders of pregnancy.
Nissim OA; Haney A; Lazenby GB
Pregnancy Hypertens; 2023 Dec; 34():47-52. PubMed ID: 37804587
[TBL] [Abstract][Full Text] [Related]
20. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
